These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25034482)

  • 1. Inhibitors of hepatitis B virus attachment and entry.
    Lempp FA; Urban S
    Intervirology; 2014; 57(3-4):151-7. PubMed ID: 25034482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
    Blanchet M; Sureau C; Labonté P
    Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
    Yan H; Li W
    Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
    Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S; Bartenschlager R; Kubitz R; Zoulim F
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
    Zhao K; Liu S; Chen Y; Yao Y; Zhou M; Yuan Y; Wang Y; Pei R; Chen J; Hu X; Zhou Y; Zhao H; Lu M; Wu C; Chen X
    Emerg Microbes Infect; 2018 Nov; 7(1):186. PubMed ID: 30459339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.
    Kaneko M; Futamura Y; Tsukuda S; Kondoh Y; Sekine T; Hirano H; Fukano K; Ohashi H; Saso W; Morishita R; Matsunaga S; Kawai F; Ryo A; Park SY; Suzuki R; Aizaki H; Ohtani N; Sureau C; Wakita T; Osada H; Watashi K
    Sci Rep; 2018 Feb; 8(1):2769. PubMed ID: 29426822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
    Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
    Fukano K; Oshima M; Tsukuda S; Aizaki H; Ohki M; Park SY; Wakita T; Wakae K; Watashi K; Muramatsu M
    J Virol; 2021 Nov; 95(24):e0093821. PubMed ID: 34613794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
    Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
    J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
    Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
    Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection.
    Takemori T; Sugimoto-Ishige A; Nishitsuji H; Futamura Y; Harada M; Kimura-Someya T; Matsumoto T; Honma T; Tanaka M; Yaguchi M; Isono K; Koseki H; Osada H; Miki D; Saito T; Tanaka T; Fukami T; Goto T; Shirouzu M; Shimotohno K; Chayama K
    J Virol; 2022 Mar; 96(5):e0168621. PubMed ID: 34985994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.
    Okuyama-Dobashi K; Kasai H; Tanaka T; Yamashita A; Yasumoto J; Chen W; Okamoto T; Maekawa S; Watashi K; Wakita T; Ryo A; Suzuki T; Matsuura Y; Enomoto N; Moriishi K
    Sci Rep; 2015 Nov; 5():17047. PubMed ID: 26592202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
    J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.